Cancer Drugs

  • US: Indian couple sentenced for using unapproved cancer drugs June 14, 2014

    New York: A US court has sentenced an Indian oncologist and his wife for using unapproved chemotherapy medications at their cancer institute for three years. Anindya Kumar Sen (65) and his wife, Patricia Posey Sen (66), of Tennessee were sentenced by US District Judge Ronnie Greer on charges of introducing misbranded...
  • Relief for Pfizer on anticancer drug June 4, 2013

    Chennai: In a relief to pharma major Pfizer, the Intellectual Property Appellate Board in Chennai has set aside the revocation of the patent of the company's anticancer drug 'Sutent'. The Board has asked the Patent Office to consider the entire matter afresh in a timebound manner, which had twice revoked...
  • New cancer drugs to be a $ 35 billion market May 23, 2013

    London: A new wave of medicines that tap the power of the immune system to fight cancer could become the biggest drug class in history, with potential sales of $35 billion a year. The sales forecast by analysts at US bank Citigroup highlights the growing excitement surrounding socalled immunotherapy after positive...
  • Novartis verdict will encourage genuine innovation: Prathiba M Singh April 3, 2013

    Prathiba M Singh, advocate for Ranbaxy and Cipla, fought the Glivec patent case against Novartis. She joined IBNLive readers for an interaction on the legal and moral compulsions behind this courtroom battle and the significance of the Supreme Court's decision for Indian pharma firms and the people of the country. Q....
  • 'US industry reviewing SC decision on Novartis' April 3, 2013

    Washington: The US industry on Wednesday said it is reviewing the order of the Supreme Court early this week that denied patent on Glivec, a cancer medication produced by Swiss drug maker Novartis, as Corporate America expressed dismay at the court verdict. "We are aware of the Supreme Court decision and...
  • 'SC order on Novartis will impact investment in India' April 3, 2013

    Washington: Expressing unease over the Supreme Court ruling against pharmaceutical giant Novartis denying the company a patent on its cancer drug, a major business advocacy group on Tuesday said that this would impact innovation and investment climate in India at a time when the country needs foreign direct investment the...
  • FTN: SC ruling on Novartis: Should cancer drugs be cheaply available? April 2, 2013

    In a landmark verdict, the Supreme Court of India dismissed a plea by the Swiss pharmaceutical giant Novartis on Monday for a patent on its cancer drug Glivec, paving way for more affordable life saving drug. ...
  • Novartis cannot ignore India's huge market: Indian Pharmaceutical Alliance April 1, 2013

    The secretary general of the Indian Pharmaceutical Alliance, DG Shah said that Novartis was merely posturing and it could not ignore the huge market that India provided to its products. ...
  • Patent case: Decision on legal recourse after reading SC judgement, says Novartis April 1, 2013

    The Supreme Court on Monday dismissed Swiss drugmaker Novartis's attempt to win patent protection for its cancer drug Glivec. ...
  • Investments in India by global pharma cos to continue: Vikas Dandekar April 1, 2013

    In a landmark verdict, the Supreme Court dismissed a plea by the Swiss pharmaceutical giant Novartis on Monday for a patent on its cancer drug Glivec, paving the way for more affordable lifesaving cancer drugs. How does it affect the Indian pharmaceutical industry and the global biggies who are looking...
  • 'Has to be a balance between innovation, affordability of drugs' April 1, 2013

    After the Supreme Court dismissed Swiss pharma company Novartis' plea for a patent on its cancer drug Glivec, pharma expert vikas Dandekar said, "This will be a far reaching decision. Innovation on one side, access and affordability on the other side. The balance has to be done". ...
  • Will now invest in India 'cautiously', says Novartis April 1, 2013

    Mumbai: Pharmaceutical giant Novartis on Monday termed the Supreme Court's judgement of not granting a patent to its cancer drug Glivec as "disappointing" and warned that though it will continue to introduce new products in India, it will now invest "cautiously". In a landmark verdict, the apex court dismissed the...
  • Cancer Patients Aid Association hails SC's verdict April 1, 2013

    In a landmark verdict, the Supreme Court of India dismissed a plea by the Swiss pharmaceutical giant Novartis on Monday for a patent on its cancer drug Glivec, paving way for more affordable life saving cancer drugs. "Generic companies will have a levy that will allow them to survive in...
  • 'SC ruling discourages innovative drug discovery' April 1, 2013

    New Delhi: Swiss pharmaceutical company Novartis, which lost its battle for patent on its cancer drug Glivec in India on Monday, said the Supreme Court's ruling discourages innovative drug discovery and is a setback for patients. "Novartis has never been granted an original patent for Glivec in India. We strongly believe...
  • Generic cancer drug to cost 92 pc less than Novartis's Glivec April 1, 2013

    New Delhi: The Supreme Court's denial of a patent to Novartis for its cancer drug Glivec in India is a blow to the pharmaceutical company, but a big relief for the patients. The generic cancer drug costs around Rs 10,000 for a monthly dosage, which is a fall of almost...
  • Timeline: Novartis's patent plea for Glivec in India April 1, 2013

    New Delhi: The Supreme Court dismissed a plea by the Swiss pharmaceutical giant Novartis on Monday for a patent on its cancer drug Glivec, paving way for more affordable life saving cancer drugs. Novartis had sought to overturn a clause in Indian Patents Law that restricts patent protection for newer...
  • SC denies patent to Novartis for Glivec April 1, 2013

    New Delhi: In a landmark verdict, the Supreme Court of India dismissed a plea by the Swiss pharmaceutical giant Novartis on Monday for a patent on its cancer drug Glivec, paving way for more affordable life saving cancer drugs. Novartis had sought to overturn a clause in Indian Patents Law...
  • SC verdict on Novartis's cancer drug Glivec today April 1, 2013

    New Delhi: The Supreme Court on Monday is likely to pronounce its verdict in the much awaited patent case involving Glivec the anticancer drug manufactured by Swiss pharmagiant Novartis priced at a whopping Rs 1.2 lakhs for a monthly dosage. The case dates back to India's denial of...
  • Natco Pharma shares surge 5.3 pc after patent ruling March 5, 2013

    Mumbai: Shares in Natco Pharma Ltd surge 5.3 per cent after an Indian patent appeals board upheld on Monday a decision to allow the company to sell a generic version of Bayer AG's cancer drug Nexavar. "It would have positive earnings implication for Natco and opens up new avenues of compulsory...
  • SC again asks Novartis to cut cancer drug price September 13, 2012

    New Delhi: The Supreme Court on Wednesday once again asked pharma company Novartis to scale down the price of its cancer drug Glivec, made from compound imatinib mesylate. The court suggested the price cut saying that the company's scheme for providing the drug free to poor patients was complicated. The court said...
  • US pushing India to hike cancer drug price July 14, 2012

    Washington: Even as President Barack Obama is plugging his signature law to lower health care costs at home, his administration is pressurising India and other countries to impose higher prices even for lifesaver cancer drugs. Obama administration's multiple "strategies to affect drug pricing abroad by using American international political muscle", according...
  • Compulsory licencing of Bayer's cancer drug is a triumph May 12, 2012

    Nata Menabde Age: 52 Designation: WHO Representative to India Education: MSc in Pharmacy, PhD in Pharmacology Career: Nearly 20 years at WHO; was deputy regional director for Europe before coming to India in 2010 Interests: Plays the piano and guitar. Likes classical music, jazz, water sports, history and Russian literature Q. What are the top three...
  • Cancer drugs to cost less, Cipla slashes prices May 5, 2012

    Mumbai: After the Indian government recently lifted a patent license, Indian pharma major, Cipla, has announced a massive reduction of up to 76 per cent in its cancer drug prices. Following the move, the price of Cipla's generic kidney cancer drug, Sorafenib, will be available at Rs 6,840 a month from...
  • Cancer 'wonder drug' affects bone density: report March 1, 2012

    Mumbai: A new concern has come to light for those battling breast cancer. A drug commonly used in India to treat the condition has been found to decrease bone density in older women. Considered a 'wonder drug' for breast cancer treatment, Exemestane, sold under the brand name, Aromasin, is commonly...
  • 5 Andhra women hospitalised after clinical trial June 18, 2011

    Hyderabad: Five women have been hospitalized in Guntur in Andhra Pradesh after they allegedly became guinea pigs for a pharma company trying out a new antibreast cancer drug. The five women were rushed to a hospital in Guntur after nausea and severe pain in the legs, after taking part in...
  • Drug developed by RSS body gets US patent June 18, 2010

    Nagpur: An anticancer drug extracted from cow urine and developed by an affiliate of the RSS has got a US patent for the third time for its antigenotoxicity properties, a senior official has said. The drug developed by RSSbacked 'Go Vigyan Anusandhan Kendra' had earlier got the US patent as a...
  • Madras High Court order makes cancer drug cheaper August 8, 2007

    Mumbai: Thirty-year-old Laxman Bhaskar has been using a screen printer to earn a living for the last eight years, working for the cancer patients aid association which has generously supported him with a salary of Rs 3, 000 apart from footing a hefty medicine bill that Laxman spends on treating...
  • Biocon unveils innovative cancer drug September 19, 2006

    Mumbai: Biocon Ltd has announced the launch of BIOMAb-EGFR, a therapeutic monoclonal antibody-based drug for treating solid tumours of epithelial origin, such as head and neck cancers. Announcing this, the company's release to BSE said this novel drug is designed to specifically target and arrest epidermal growth factor receptor (EGFR)...